MindWalk (NASDAQ:HYFT) Rating Lowered to “Strong Sell” at Zacks Research

MindWalk (NASDAQ:HYFT) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday,Zacks.com reports.

MindWalk Price Performance

HYFT traded down $0.14 during midday trading on Monday, reaching $2.00. 703,778 shares of the company’s stock traded hands, compared to its average volume of 960,888. MindWalk has a 52 week low of $0.27 and a 52 week high of $3.25. The firm has a market capitalization of $92.31 million, a price-to-earnings ratio of -3.33 and a beta of 0.48.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.